-

Evolus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the H.C. Wainwright 24th Annual Global Investment Conference.

Event:

H.C. Wainwright 24th Annual Global Investment Conference

Date:

Monday, September 12, 2022

Time:

Available on-demand starting at 7:00 am ET

An audio webcast of this event will be available on the investor relations section of Evolus’ website at www.evolus.com. A replay of the webcast will be available for 90 days after the date of the presentation.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Visit us at www.evolus.com, and follow us on LinkedIn, Twitter, Instagram or Facebook.

Jeuveau® is a registered trademark of Evolus, Inc.

Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Contacts

Investor/Media Contact:
David K. Erickson, Evolus, Inc.
Vice President, Investor Relations
Tel: 949-966-1798
Email: david.erickson@evolus.com

Industry:

Evolus

NASDAQ:EOLS
Details
Headquarters: Newport Beach, CA
CEO: David Moatazedi
Employees: 150
Organization: PUB
Release Summary
Evolus announces that members of its management team will be participating in the H.C. Wainwright 24th Annual Global Investment Conference.
Release Versions
English
$Cashtags
$EOLS

Contacts

Investor/Media Contact:
David K. Erickson, Evolus, Inc.
Vice President, Investor Relations
Tel: 949-966-1798
Email: david.erickson@evolus.com

Social Media Profiles
Follow Us on LinkedIn
More News From Evolus

Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlook

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the third quarter ended September 30, 2026. “Our third quarter results demonstrate the continued strength of our commercial execution and the progress we are making in building a diversified global performance beauty company,” said David Moatazedi, President and Chief Executive Offic...

Evolus to Participate in Upcoming Investor Conferences in New York and London

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team will participate in two upcoming investor conferences in New York and London: The Stifel Healthcare Conference, where management will participate in a fireside chat and host investor meetings on Wednesday, November 11, 2026, in New York City. The fireside chat is scheduled for 2:0...

Evolus to Report Third Quarter Financial Results on November 4, 2026

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2026 financial results on Wednesday, November 4, 2026, after the U.S. financial markets close.Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management’s remarks.To p...
Back to Newsroom